Anna's interest in research began in 2004, when she was an ophthalmic ward nurse, with the development and implementation of a pain assessment tool specifically for the use in Ophthalmology. This interest progressed to her becoming a research nurse, only the second research nurse to be appointed at the Oxford Eye Hospital. Most of Anna’s research at that time was looking at Age Related Macular Degeneration (AMD). This has now expanded into Gene Therapy related trials working with Professor MacLaren and his team.
Having gained a research management qualification in 2013, Anna now works as Research Sister for the Eye Research Group Oxford (ERGO) where she coordinates numerous gene therapy trials. With over 20 years of NHS experience, Anna is well qualified to support everyone from her junior colleagues to consultants commencing new studies, and is dedicated to being part of a progressive innovative research team.
Vector shedding and immunology results from a gene therapy clinical trial for Choroideremia
- ARVO poster.pdf
- PDF document 1.2 MB
Previously involved in:
Phase 1 gene therapy for Choroideremia
Ongoing / new projects:
REGENERATE (phase II gene therapy). Recruitment closed
NIGHT (observational study marring out the natural progression of Choroideremia). Recruitment closed
STAR (phase III gene therapy for Choroideremia). Recruitment closed
XIRIUS (phase I/II gene therapy for Retinitis Pigmentosa) RP. Recruitment suspended until mid 2020.
XIRIUS (phase III due to commence autumn 2020)
XOLARIS - observational study mapping out the natural progression of RP. Recruitment open.
SOLSTICE - Long term follow up to evaluate the safety and efficacy of treated gene therapy patients with Choroideremia & Retinitis Pigmentosa. Recruitment open.
STAR X - Treatment of previous control patients from phase III CHM trial. In set up.